Abbott Laboratories
Moat Score — Abbott Laboratories
Total Moat Score
18 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Abbott holds strong brands (FreeStyle Libre, Similac, Ensure), a deep device and diagnostics patent estate, and FDA/regulatory approvals that are costly and time-consuming for new entrants to replicate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 3 / 5 | Scale manufacturing and global distribution across four segments give Abbott cost efficiencies, particularly in diagnostics and nutrition, though it is not uniquely low-cost versus similarly scaled peers like Danaher or Nestlé. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | FreeStyle Libre commands strong pricing as a category leader, but diagnostics faces post-pandemic normalization pressure and nutrition/established pharma operate in more price-sensitive, reimbursement-driven or emerging-market channels. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | Libre's connected app and physician data-sharing tools create modest ecosystem stickiness, but this is a minor factor relative to Abbott's core hardware and consumable economics. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | A large installed base of diagnostic lab instruments locks in recurring reagent sales, and patients/physicians build strong habitual reliance on continuous glucose monitors and cardiac devices once adopted, making switching costly and disruptive. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | In glucose monitoring, Abbott and Dexcom effectively duopolize a fast-growing, technically demanding category, but Abbott's other three segments (diagnostics, nutrition, pharma) face broader, more efficiently contested competitive sets. |